WHO Sounds Concern Over Critical Shortage of Obesity Injections
Fewer than 10% of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, warns the WHO as it releases its initial advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
Per projections, more than two billion are projected to be obese by 2030 without intervention.
"The new guidance affirms that obesity is a long-term condition that can be treated with holistic and lifelong support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are major barriers to broad availability to the jabs that can assist patients in reducing significant body mass, explains the organization.
Weight-Loss Drug Supply Crisis
Even in the present best projected case, the production of these medications might only reach around 100 million people – less than 10% of the global need, as stated by the health organization.
The recommendation calls on governments and firms to expand access, by approaches such as patent sharing.
A patent on the active ingredient – the core ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple countries in 2026.
The Way Obesity Injections Function
These medications mimick a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so users consume fewer calories.
People usually see weight reduction in the initial weeks of commencing the weekly injections.
Studies points to users may regain a significant portion a year later of discontinuing the drug, because their normal food cravings come back.
To be carrying excess weight elevates your risk for developing medical conditions, such as diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts individuals in every country and was linked to over three and a half million deaths worldwide in 2024, per the health agency.
